Basic Information | Post buying leads | Suppliers |
Name |
Aurothioglucose |
EINECS | 235-365-7 |
CAS No. | 12192-57-3 | Density | g/cm3 |
PSA | 115.45000 | LogP | -2.01870 |
Solubility | N/A | Melting Point |
N/A |
Formula | C6H11 Au O5 S | Boiling Point | °Cat760mmHg |
Molecular Weight | 392.20 | Flash Point | °C |
Transport Information | N/A | Appearance | N/A |
Safety | Confirmed carcinogen with experimental carcinogenic and neoplastigenic data. A deadly human poison by an unspecified route. An experimental poison by intramuscular route. Moderately toxic by subcutaneous and intravenous routes. Human systemic effects: nausea or vomiting, cholestatic jaundice, and eye effects. An experimental teratogen. Other experimental reproductive effects. See also GOLD COMPOUNDS. When heated to decomposition it emits very toxic fumes of SOx. Used to treat rheumatoid arthritis. | Risk Codes | 42/43 |
Molecular Structure | Hazard Symbols | ||
Synonyms |
D-Glucose,1-thio-, S-gold deriv. (6CI);Gold, (1-thio-D-glucopyranosato)- (8CI);Gold,(1-thio-D-glucopyranosato-O2,S1)-;D-Glucopyranose, 1-thio-, gold complex;(D-Glucopyranosylthio)gold;Aureotan;Auromyose;Aurothioglucose;Aurumine;Authron;Brenol;Glucose, 1-thio-, gold salt (1:1);Glysanol B;Goldthioglucose;Gold, (D-glucopyranosylthio)-;Oronol;Solganal;Solganal B; |
Chemistry informtion about 1-Aurothio-D-Glucopyranose(CAS NO.12192-57-3) is:
IUPAC Name: gold(1+); (3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxane-2-thiolateSynonyms: (1-D-Glucosylthio)Gold ;(1-Thio-D-Glucopyranosato)-Gol ;(D-Glucopyranosylthio)-Gol ;(D-Glucopyranosylthio)Gold ;1-Aurothio-D-Glucopyranose ;1-Thio-D-Glucopyranose,Goldcomplex ;1-Thio-D-Glucopyranose,Monogold(1+)Salt ;1-Thio-Glucopyranose,Monogold(1+)Salt
MF: C6H11AuO5S
MW: 392.18
EINECS: 235-365-7
Product Categories: Organometallics
Storage temp.: 2-8°C
Merck: 13,887
Following is the molecular structure of 1-Aurothio-D-Glucopyranose(CAS NO.12192-57-3) is:
1-Aurothio-D-Glucopyranose(CAS NO.12192-57-3) was used to treat rheumatoid arthritis and used to produce experimental obesity in rodents.
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
chicken | LD50 | intravenous | 1gm/kg (1000mg/kg) | Poultry Science. Vol. 52, Pg. 926, 1973. | |
chicken | LDLo | intramuscular | 300mg/kg (300mg/kg) | BRAIN AND COVERINGS: OTHER DEGENERATIVE CHANGES SPINAL CORD: OTHER DEGENERATIVE CHANGES | Toxicology and Applied Pharmacology. Vol. 35, Pg. 223, 1976. |
man | LDLo | unreported | 3mg/kg (3mg/kg) | Sammlung von Vergiftungsfaellen. Vol. 10, Pg. 101A, 1939. | |
man | TDLo | intramuscular | 3357ug/kg/4W- (3.357mg/kg) | SENSE ORGANS AND SPECIAL SENSES: OTHER: EYE | Journal of Rheumatology. Vol. 12, Pg. 619, 1985. |
man | TDLo | intramuscular | 5500ug/kg/10W (5.5mg/kg) | LUNGS, THORAX, OR RESPIRATION: COUGH LUNGS, THORAX, OR RESPIRATION: DYSPNEA | Southern Medical Journal. Vol. 88, Pg. 644, 1995. |
mouse | LD50 | intraperitoneal | 2gm/kg (2000mg/kg) | LIVER: OTHER CHANGES | Proceedings of the Society for Experimental Biology and Medicine. Vol. 70, Pg. 498, 1949. |
mouse | LDLo | subcutaneous | 1650mg/kg (1650mg/kg) | Experimental Medicine and Surgery. Vol. 3, Pg. 146, 1945. | |
women | TDLo | intramuscular | 2600ug/kg/15D (2.6mg/kg) | GASTROINTESTINAL: NAUSEA OR VOMITING LIVER: OTHER CHANGES | Arthritis and Rheumatism. Vol. 27, Pg. 230, 1984. |
women | TDLo | intramuscular | 14402ug/kg/2Y (14.402mg/kg) | KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)" KIDNEY, URETER, AND BLADDER: PROTEINURIS KIDNEY, URETER, AND BLADDER: OTHER CHANGES IN URINE COMPOSITION | Taisha. Molecular Medicine Vol. 12, Pg. 1435, 1975. |
women | TDLo | parenteral | 2700ug/kg/4W- (2.7mg/kg) | LIVER: "JAUNDICE, CHOLESTATIC" | Journal of Rheumatology. Vol. 11, Pg. 843, 1984. |
IARC Cancer Review: Group 1 IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man . 7 (1987),p. 56.(World Health Organization, Internation Agency for Research on Cancer,Lyon, France.: ) (Single copies can be ordered from WHO Publications Centre U.S.A., 49 Sheridan Avenue, Albany, NY 12210) ; Animal Limited Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man . 13 (1977),p. 39.(World Health Organization, Internation Agency for Research on Cancer,Lyon, France.: ) (Single copies can be ordered from WHO Publications Centre U.S.A., 49 Sheridan Avenue, Albany, NY 12210) .
Confirmed carcinogen with experimental carcinogenic and neoplastigenic data. A deadly human poison by an unspecified route. An experimental poison by intramuscular route. Moderately toxic by subcutaneous and intravenous routes. Human systemic effects: nausea or vomiting, cholestatic jaundice, and eye effects. An experimental teratogen. Other experimental reproductive effects. See also GOLD COMPOUNDS. When heated to decomposition it emits very toxic fumes of SOx.
Hazard Codes:
Xn
Risk Statements:
R42/43:May cause sensitization by inhalation and skin contact.
Safety Statements:
S22:Do not breathe dust.
S36/37:Wear suitable protective clothing and gloves.
S45:In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)
RIDADR: 2811
HazardClass: 6.1(b)
PackingGroup: III
First Aid Measures about 1-Aurothio-D-Glucopyranose(CAS NO.12192-57-3) is:
Ingestion: If swallowed, wash out mouth with water provided person is conscious. Call a physician.
Inhalation: If inhaled, remove to fresh air. If breathing becomes difficult, call a physician.
Skin: In case of skin contact, flush with copious amounts of water for at least 15 minutes. Remove contaminated clothing and shoes. Call a physician.
Eyes: In case of contact with eyes, flush with copious amounts of water for at least 15 minutes. Assure adequate flushing by separating the eyelids with fingers. Call a physician.